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Cerebellar stem cells act as medulloblastoma-initiating cells in a
mouse model and a neural stem cell signature characterizes a
subset of human medulloblastomas
Abstract
Cells with stem cell properties have been isolated from various areas of the postnatal mammalian brain,
most recently from the postnatal mouse cerebellum. We show here that inactivation of the tumor
suppressor genes Rb and p53 in these endogenous neural stem cells induced deregulated proliferation
and resistance to apoptosis in vitro. Moreover, injection of these cells into mice formed
medulloblastomas. Medulloblastomas are the most common malignant brain tumors of childhood, and
despite recent advances in treatment they are associated with high morbidity and mortality. They are
highly heterogeneous tumors characterized by a diverse genetic make-up and expression profile as well
as variable prognosis. Here, we describe a novel ontogenetic pathway of medulloblastoma that
significantly contributes to understanding their heterogeneity. Experimental medulloblastomas
originating from neural stem cells preferentially expressed stem cell markers Nestin, Sox2 and Sox9,
which were not expressed in medulloblastomas originating from granule-cell-restricted progenitors.
Furthermore, the expression of these markers identified a subset of human medulloblastomas associated
with a poorer clinical outcome.
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Abstract
Cells with stem cell properties have been isolated from various areas of the postnatal 
mammalian brain, most recently from the postnatal mouse cerebellum. We show here that 
inactivation of the tumour suppressor genes Rb and p53 in these endogenous neural stem 
cells induced deregulated proliferation and resistance to apoptosis in vitro. Moreover, injection 
of these cells into mice formed medulloblastoma. Medulloblastomas are the most common 
malignant brain tumours of childhood and despite recent advances in treatment they are 
associated with high morbidity and mortality. They are highly heterogeneous tumours 
characterised by diverse genetic make-up and expression profile as well as variable prognosis. 
Here, we describe a novel ontogenetic pathway of medulloblastoma which significantly 
contributes to understanding their heterogeneity. Experimental medulloblastoma originating 
from neural stem cells preferentially expressed stem cell markers Nestin, Sox2 and Sox9, 
which were not expressed in medulloblastoma originating from granule cell restricted 
progenitors. Furthermore, the expression of these markers identified a subset of human 
medulloblastoma associated with a poorer clinical outcome.  
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Introduction 
Neural stem cells (NSCs) are self-renewing and multipotent cells, which allow some degree of 
regeneration and plasticity in the adult brain. While their presence in the subventricular zone 
(SVZ) surrounding the adult lateral ventricle of the telencephalon and in the subgranular zone 
(SGZ) of the dentate gyrus has been shown in vivo and their characteristics analysed in vitro, 
the existence of cells with similar properties in the postnatal cerebellum has been suggested 
only recently (cNSCs) (Lee et al., 2005). It is intriguing to think that NSCs populating specific 
brain areas might be a novel putative cell of origin of brain tumours. Preliminary evidence to 
support this hypothesis has been provided by a study which showed that stimulation of SVZ 
stem cells with PDGF, a signalling pathway known to be deregulated in brain tumours of glial 
origin, led to hyperplastic growth (Jackson et al., 2006). More recently, two papers have shown 
that inactivation of the tumour suppressor genes p53 and PTEN or Nf1 and p53 in SVZ 
stem/progenitor cells induces high grade astrocytomas (Alcantara Llaguno et al., 2009; Zheng 
et al., 2008).  However, both studies have used either Nestin driven Cre expression or 
intraventricular adenovirus mediated Cre delivery to target progenitor cells and these 
approaches do not allow to specifically target stem cells. In fact, other reports showed that 
postnatal NSCs are remarkably resistant to neoplastic transformation. Foroni et al. were able 
to culture these cells in vitro with the neurosphere (NS) assay for over a year and did not 
detect any evidence for neoplastic transformation in vivo, even after transduction of the cells 
with Myc and Ras oncogenes (Foroni et al., 2007).  
Medulloblastomas are heterogeneous neoplasms characterised by variable prognosis and 
response to current therapies. Currently, the best predictors of prognosis are the patient’s age 
at diagnosis, the extent of postoperative residual tumour and the presence of metastatic 
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disease. However, these clinical parameters have limitations in their predictive value and do 
not provide mechanistic insights into the pathogenesis of a specific neoplasm or into the 
response of the tumour to therapy, as biomarkers would do. Very few biomarkers have been 
identified for medulloblastoma, but they have not yet been extensively validated or are highly 
controversial (Crawford et al., 2007). 
A subset of medulloblastoma is believed to originate from committed granule cell progenitors 
(GCPs) located in a secondary germinal layer unique to the developing cerebellum, the 
external granular layer (EGL), that will give rise to granule neurons (reviewed in (Behesti & 
Marino, 2009). Heterozygosity for the Ptc gene, a key member of the Shh signalling pathway, 
has been shown to predispose to medulloblastoma formation in a hereditary tumour syndrome, 
the Gorlin Syndrome (Hahn et al., 1996; Johnson et al., 1996) and in genetically engineered 
mice (Goodrich et al., 1997). Recently, acquisition of granule cell precursor identity has been 
suggested to be critical for medulloblastoma formation in mouse models, where aberrant Shh 
pathway activation was driving tumourigenesis (Schuller et al., 2008; Yang et al., 2008). These 
models have significantly contributed to our understanding of the pathogenesis of these 
neoplasms in young children (Eberhart, 2003; Marino et al., 2000; Tong et al., 2003; Weiss et 
al., 2002). However, the occurrence of medulloblastoma in older children and adults, where 
such progenitor cells are no longer present, is not explained by these models. Moreover, 
mutations in the PTC gene and other related Shh pathway members have been found only in a 
minority of sporadic medulloblastoma (25% (Zurawel et al., 2000)).  
We have previously developed a mouse model of medulloblastoma by selective inactivation of 
the tumour suppressor genes Rb and p53 in GCPs of the EGL. After a latency of 20 weeks 
medulloblastoma occur in the cerebellum with 100% penetrance. These tumours show 
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remarkable similarities to the large cell anaplastic variant of human medulloblastoma, including 
similar histology, highly aggressive behaviour (Marino et al., 2000) and acquisition of additional 
genetic mutations mainly affecting N-Myc (Shakhova et al., 2006). Here we have taken 
advantage of this powerful experimental system in which medulloblastoma arise with full 
penetrance when permissive cells are targeted to address the question of whether postnatal 
cNSCs can act as medulloblastoma initiating cells and whether different ontogenetic 
mechanisms can play a role in explaining the heterogeneity of these tumours in humans.  
 
Materials and methods 
Mouse strains 
RbloxP/loxP;p53loxP/loxP;R26R-LacZ homozygous mutant mice and Math1GFP transgenic mice 
were used (Lumpkin et al., 2003; Marino et al., 2000). Allograft studies were performed in NOD 
SCID mice. All procedures had Home Office approval (PPL 70/6452). 
 
cNSC isolation, culture and LoxP sites recombination 
Pups were decapitated at p7 and single cells were prepared from the cerebellum using the 
neural tissue dissociation kit (Miltenyi). To enrich for cNSCs, MACS-sorting for Prominin1 
(Miltenyi) was used.  Flow cytometry after immunolabeling of the cells with Prominin1-APC-
antibodies (Miltenyi) showed a 10-fold enrichment of the CD133-positive cells, in agreement 
with published data(Pfenninger et al., 2007). Flow cytometry for GFP on CD133-positive and 
CD133-negative fractions isolated from Math1-GFP cerebella revealed a percentage of GFP 
positive cells of 34.2% and 93.3% respectively. Culturing conditions: DMEM/HamF12 medium 
(Invitrogen) , 1% Pen/Strep (Invitrogen), 20ng/mL EGF / bFGF (Peprotech) and 2% B27 
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(Invitrogen). Cells were grown at 37 ºC and 5%CO2. EGF and bFGF was supplemented every 
3 days at 20ng/mL. NS were repeatedly dissociated -at least three times- mechanically to 
single cells and replated in fresh medium before any assay was carried out. Flow cytometry for 
GFP revealed no positive cells at this time point. 
Deletion/inactivation of Rb and p53 was achieved in vitro by adenoviral-mediated Cre delivery 
in cNSCs isolated from RbloxP/loxP;p53loxP/loxP;RosaLacZ homozygous mice. Adenoviral vectors 
(Clontech) expressing Cre or GFP were used. The cells were infected with Adeno-Cre or 
Adeno-GFP at a MOI of 2 (2.5 x 106 PFU/μl) one day after mechanical dissociation. To assess 
the efficiency of recombination, Adeno-Cre infected cells were stained with X-gal according to 
standard protocols. PCR analysis of Cre-mediated recombination was performed on genomic 
DNA extracted from NS isolated from heterozygous compound mutant mice according to 
published protocols (Marino et al., 2000). 
 
Characterization of mutant cNSC 
Proliferation was assessed with AlamarBlue assay (BioSource). 8000 cells per well were 
plated in a 96-well plate (BD Falcon) and proliferation was assessed daily for 7 days by 
measuring absorption at 570nm. Self-renewal curves were obtained by performing serial 
dilutions of cells (from 500 cells to 4 cells per well) in 24-well plates (BD Falcon) and counting 
the number of resulting NS in each well after 5 days in culture. The results were plotted into 
self-renewal curves. For analysis of apoptosis 5 x 105 cells were labeled with Annexin V 
(Invitrogen), dead cells were labeled with DAPI (Sigma); flow cytometry was performed with a 
LSR II flow cytometer (BD Biosciences) and data calculated using the FACSDiva software (BD 
Biosciences). 
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For assessment of multipotency, NS were seeded on laminin-coated coverslips and grown in 
Neurobasal medium (Invitrogen) supplemented with 1% B27 (Invitrogen) for 7 days. 
Undifferentiated NS were seeded on laminin-coated multi-chamber slides (BD Biosciences) for 
20min to induce adhesion and facilitate subsequent processing. Both undifferentiated NS and 
differentiated cells were fixed in 4% paraformaldehyde. See Supplementary material for list of 
antibodies. 
NS were dissociated mechanically one day before subcutaneous injection. 250’000 Rb-/-;p53 -
/- cNSCs were injected subcutaneously into the right flank of the animal, whereas GFP 
infected or uninfected control cNSCs were injected into the left flank. Palpable tumours were 
surgically removed upon culling the animal with CO2. All animals were culled 140 days after 
injection. X-gal staining was performed according to standard protocols. Tumours were fixed in 
4% buffered formalin, embedded in paraffin, cut and processed according to standard 
protocols. 
Expression analysis on cNSC and murine tumours by qRT-PCR or RT-PCR 
RNA from adult cerebellum as well as tumours were extracted using the Trizol™ method 
according to standard protocols and DNase treated using Amp Grade DNase I (Invitrogen) 
according to the manufacturer’s descriptions. RNA from pre-injection tertiary neurosphere-
derived cells was extracted using the Qiagen RNeasy Micro Kit (Qiagen) and on-column 
DNase treatment was performed according to the manufacturer’s descriptions. First strand 
cDNA synthesis was carried out using the Superscript III Reverse Transcriptase kit 
(Invitrogen). The expression levels of Math1, Bcl-2, and N-myc were compared using SYBR® 
Green (Sigma) qRT-PCR on a 7500 ABI machine with previously published primers (Nmyc; 
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Yang et al. 2008) or the following primers: Bcl-2; Forward: GAGCGTCAACAGGGAGATGT, 
Reverse: CTCACTTGTGGCCCAGGTAT, Math1; Forward: ACATCTCCCAGATCCCACAG, 
Reverse: ACAACGATCACCACAGACCA. Expression of the following genes was detected 
using RT-PCR and the following published or newly designed primers: GABAR6; Drescher et 
al 1993, Gli1; Yang et al. 2008, Ptc-2; Forward: TGGCTTCGAGCTTACTTCCA, Reverse: 
CCCAGCTTCTCCTTGGTGTA, ActB; Forward: TGTTACCAACTGGGACGACA, Reverse: 
GGGGTGTTGAAGGTCTCAAA. 
Histological Analysis 
Ethical approval was obtained from the SPUK Zurich (StV 6-2005) for the studies on human 
medulloblastoma. Medulloblastoma obtained from the archives of the Pathology Department of 
the University Hospital of Zurich and the Cantonal Hospital of Aarau, Switzerland between 
1986 and 2004 were used to construct TMA. Sixty-six samples were primary neoplasms and 5 
were recurrences. 
All histological slides were independently re-evaluated by two neuropathologists. Five human 
tumours were nodular/desmoplastic and 8 tumours were large cell anaplastic variant, all other 
specimens were classified as classic type. Survival data with a medium follow-up period of 66 
months (range 1 – 189 months), progression data, and M-stage were available from 56 
patients. There were 44 paediatric (<16 years) and 18 adult (16 years) cases. The age of 3 
patients was unknown. Two cores (0.6 mm in diameter each) from representative areas were 
taken for each medulloblastoma and the presence of tumour cells was confirmed on a 
haematoxylin and eosin stained slide of the TMA. See Supplementary material for list of 
antibodies. 
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Statistics
Contingency table analysis and Chi-square tests were applied to study the relationship 
between protein expression, histological, biological and clinical parameters. Survival curves 
were plotted according to the Kaplan-Meier method. A log rank test was applied to examine 
the relationship between molecular data and tumor-specific survival or tumor progression. For 
progression analysis, patients were censored at the time of their last clinical control showing 
no evidence of progressed disease. For tumor-specific survival analysis, patients were 
censored at the time of their last clinical control. All statistics were performed using StatView 
5.0.1 and SPSS 12.0.1 for Windows.
 
Results and discussion 
cNSC were isolated from postnatal day 7 (P7) cerebella by magnetic activated cell sorting 
(MACS) using anti-prominin/CD133 beads. This is currently the best characterised marker to 
isolate NSCs of neuroepithelial (NE) origin (Corti et al., 2007) and it has been shown to be 
expressed in both white matter cNSC and in periventricular cells of the 4th ventricle (Lee et al., 
2005 and Gensat) . 
Firstly, to assess whether GCPs were present in the CD133-positive fraction, the method was 
applied to the cerebella of P7 Math1-GFP mice, transgenic mice in which GFP expression is 
driven by the Math1 promoter, a helix-loop-helix (HLH) transcription factor specifically 
expressed in GCPs (Fig.1a, upper row left) (Lumpkin et al., 2003). Flow cytometry performed 
on the CD133-negative (unlabelled) and CD133-positive (labelled) fraction revealed that while 
93.3% of cells contained in the CD133-negative fraction were GFP positive, only 34.2% of the 
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total number of cells contained in the CD133-positive fraction  were GFP positive (Fig.S1a,b). 
These data are in keeping with a considerable enrichment for cNSC and precursors of non 
granule cell lineage in the CD133 positive fraction. Upon plating, GFP positive cells, which 
were morphologically recognizable as GCPs, were seen in the CD133-negative fraction 
(Fig.1b, left) however, no GFP positivity was detected in the neurospheres (NS) that formed in 
the CD133-positive fraction (Fig.1b, right). To further enrich for cNSC and to make sure that 
the residual GCPs were eliminated from the cultures, NS arising in the CD133-positive fraction 
were repeatedly dissociated and replated (at least three times). Under continuous exposure to 
EGF and bFGF, only NSCs and highly undifferentiated progenitors proliferate, whereas 
committed precursors and terminally differentiated cells –such as GCPs- are eliminated from 
the culture (Galli et al., 2008). Flow cytometry performed on single cells 24h after splitting 
tertiary NS revealed no GFP positive cells (Fig.S1d). Morphological analysis of the cultures 
confirmed absence of GFP positive cells (Fig.1c). Moreover, no GFP expression was noted in 
NS originating from these cells (quaternary NS) upon fixation and visual confocal analysis 
(Fig.1e).  
 
NS originating from the CD133 positive cells expressed stem cell markers such as CD133, 
Nestin, Bmi1 and Sox2 in a proportion of the cells (Fig.1f). These cells were capable of long-
term self renewal as assessed by repeated dissociation and replating in the same NS forming 
culturing conditions (Fig.S2) and were multipotent as assessed by their capacity to differentiate 
into neurons, oligodendrocytes and astrocytes when grown in a differentiation-inducing 
medium (Fig.1g). All experiments were repeated at least three times from three independent 
primary preparations. 
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Next, we isolated cNSCs from homozygous compound mutant mice carrying floxed alleles for 
Rb, p53 (Marino et al., 2000; Rajewsky et al., 1996) as well as R26R-LacZ (Soriano, 1999) and 
we deleted Rb and p53 in these cells by adenovirus-mediated Cre-induced recombination in 
vitro (Akagi et al., 1997). The efficiency of recombination of the floxed alleles was assessed by 
X-gal staining (R26R-LacZ  allele) and PCR analysis performed on NS isolated from 
heterozygous compound littermates (Rb and p53 alleles). All NS were X-gal positive (Fig.2a 
left) and all cells had lost the Rb floxed band upon adenovirus mediated recombination (Fig.2b 
left). The efficiency of recombination of the p53 allele was very high but a small proportion of 
cells still retained the floxed allele (Fig.2b middle and right), thus implying, in agreement with 
previous reports (Meuwissen et al., 2003), that the p53 locus is potentially less accessible for 
the Cre enzyme. Cell viability, as assessed by the Alamar Blue assay, was significantly higher 
in NS lacking Rb and p53 as compared to control cells infected with Adeno-GFP (Fig.2c). 
Accordingly, the mutant cultures showed a higher number of NS with a larger diameter 
compared to controls (Fig.2d). We then assessed whether lack of Rb and p53 would influence 
the number of cells capable of giving rise to NS in these cultures. In a clonogenic assay, we 
found a significantly higher (2-fold) number of quaternary NS arising from the same number of 
plated cells upon dissociation of tertiary NS (Fig.2e). Interestingly, we found a significant 
resistance to apoptosis of the cells contained in the mutant NS, as assessed by Annexin V 
staining and flow cytometry (5% compared to 18% in controls) (Fig.2f). Finally, mutant cNSC 
still exhibited multipotency and were able to give rise to neurons, oligodendrocytes and 
astrocytes after induction of differentiation in vitro, as determined by immunostaining for 
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astrocytic (GFAP), oligodendroglial (O4) and neuronal (β III Tubulin) markers, although they 
gave rise to a lower number of differentiated cells (Fig.2g).  
To exclude differences, such as for example in viral toxicity between the two viruses, all 
experiments were performed on non transgenic cells treated either with Adeno-Cre or with 
Adeno-GFP (Fig.2a, left and middle) and no significant difference was noted in the various 
assays. 
 
To assess whether postnatal cNSCs lacking Rb and p53 were able to act as medulloblastoma 
initiating cells in vivo, we injected the cells subcutaneously into the flanks of NOD SCID mice. 
This strategy has recently been reported to yield a very high incidence of medulloblastoma, 
when mutant GCPs were injected (Zhao et al., 2008) and was chosen to permit injection of a 
large number of cells. Five mice out of thirty four injected (14.7%) developed tumours (Fig.2a 
left) between 67 and 81 days after injection, whereas no tumour growth was detected when 
control GFP-infected NS were injected. Whole mount X-gal staining confirmed that neoplasms 
originated from the injected cells (Fig.3a). The histological characteristics of the tumours were 
high cellularity, high nuclear-cytoplasmic ratio, moderate nuclear pleomorphism, nuclear 
moulding and high mitotic and apoptotic activity (Fig.3a). Immunohistochemistry revealed 
strong and homogeneous positivity for Synaptophysin , Neuron Specific Enolase (NSE)  and 
Map2 (Fig.3a) in the majority of the tumour cells, while GFAP was decorating only few isolated 
cells. Morphological and immunohistochemical features were those of a medulloblastoma with 
diffuse anaplasia.  
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To further substantiate our conclusion that the tumours were indeed originating from 
progenitors of non-granule cell lineage, we set out to assess expression of Math1 in the 
transformed cells at the time we would inject them subcutaneously (transformed pre-injection 
cNSC, n=2), in cNSC medulloblastoma (n=3) and in EGL medulloblastoma (n=3). Expression 
of Math1 in the adult cerebellum (n=3) or in the adult skeletal muscle (n=1) and in 
medulloblastoma originating in ptc+/- mice (n=3) was used as negative and positive controls 
respectively. No significant difference in Math1 expression level was found between 
transformed pre-injection cNSC and cNSC medulloblastoma and tissue known not to express 
Math1 such as adult cerebellum and adult skeletal muscle (Fig.3b). On the contrary the 
expression of Math1 in EGL medulloblastoma was high and very similar to the expression level 
detected in ptc+/- medulloblastoma (Fig.3b). Similarly no expression of GABARα6 and only 
very weak expression of Gli1 was detected in all three cNSC medulloblastoma as compared to 
the strong expression of both genes in the adult cerebellum and in 2/3 EGL medulloblastoma 
(Fig.3c). Interestingly, expression of ptch2 and N-Myc, which we found significantly 
upregulated in EGL medulloblastoma (Shakhova et al., 2006), was significantly lower in cNSC 
medulloblastoma (Fig.S3), therefore implying that a different molecular mechanism might be 
involved in the pathogenesis of these tumours. 
These data show that progenitors of non-granule cell lineage (CD133+,Math1-) can give rise to 
medulloblastoma. Previous work has shown that despite targeting Shh activation to NSCs 
during embryonic development, acquisition of granule cell precursor identity was needed for 
medulloblastoma formation (Schuller et al., 2008; Yang et al., 2008). Our data support the 
notion that different combinations of genetic mutations might be needed to transform cells at 
different developmental stages. The tumour incidence upon injection of Rb-/-;p53-/- cNSCs was 
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low, as compared to the very high incidence of medulloblastomas when GCPs were targeted. 
This might imply that either cNSCs have protective mechanisms in place to prevent their 
neoplastic transformation or that the microenvironment has an important influence on tumour 
growth. Our experimental setting did not allow us to inject subcutaneously also the CD133 
negative fraction as these cells are mainly GCPs which become postmitotic when cultured. To 
induce recombination in vitro by means of Adeno-Cre infection we would have had to passage 
them. However, Zhao et al (Zhao et al., 2008) have shown a very high incidence of 
medulloblastoma when mutant GCPs were injected subcutaneously, in a similar way as we do, 
therefore raising the possibility that a cell intrinsic mechanism might be involved in the low 
tumour take. Although we cannot completely exclude that partial recombination of the p53 
allele might be responsible in part for the low tumour incidence, this is unlikely as the 
recombination was partial also when we targeted GCPs. Taken together these data support 
the conclusion that a cell intrinsic mechanism is most likely to be involved in the resistance to 
neoplastic transformation of postnatal cNSCs. 
 
In order to determine whether the expression of stem cell markers could be useful in 
discriminating between medulloblastoma arising from cNSC and those originating from GCPs, 
we tested expression of two such markers, Sox2 and Sox9 (Cheung & Briscoe, 2003; Ellis et 
al., 2004; Ferri et al., 2004) on three cNSC medulloblastoma and on a tissue microarray (TMA) 
containing 24 murine EGL medulloblastoma originating from GCPs that lacked Rb and p53 
(Marino et al., 2000). 
We found strong and homogeneous expression of Sox2 and Sox9 in the majority of cells of 
cNSC medulloblastoma (95% positive cells) as well as expression of nestin (which is only 
Sutter et al.     15 
weakly expressed in GCPs) in a significant proportion of tumour cells (60 % positive cells) 
(Fig.4a upper row). Conversely, expression of these markers was not seen in the vast majority 
of the tumour cells of EGL medulloblastoma, where they decorated only few scattered cells 
within the tumour (5% positive cells) (Fig.4a lower row). Western blot analysis of 6 of these 
EGL medulloblastomas confirmed absence of Sox2 expression (Fig.4b). Moreover, another 
example of medulloblastoma arising from GCPs in ptc +/- mice displayed comparable results 
with only few scattered cells that were positive for Sox2 (Fig.4c).  
Then we analyzed the expression of Sox2 and Sox9 in the developing cerebellum of non 
transgenic mice. At embryonic day (E) 18.5 we found strong expression of both markers in all 
cells of the NE (Fig.4d upper row) while GCPs of the EGL were mainly negative with only few 
of these cells expressing these markers very weakly (Fig.4d lower row and inset). At the peak 
of the clonal expansion phase of GCPs (P7) no expression was seen in these highly 
proliferating cells, while Bergmann glia cells and scattered cells within the IGL and in the white 
matter expressed Sox2 and Sox9 (Fig.4e and data not shown). A fraction of these cells was 
also proliferating, as assessed by BrdU staining (Fig.4e) and was co-expressing nestin 
(Fig.4e). Later, when the development of the cerebellum is complete (P20), Sox2 positive cells 
were still present in the same anatomical locations as described at P7 (Fig.4f).  
These results raise the possibility that expression of stem cell markers such as Sox2, Sox9 
and potentially nestin identifies medulloblastoma arising from cNSCs, in keeping with the 
developmental expression profile of these markers.  
 
Next, we analysed whether NE stem cell markers were expressed in human medulloblastoma. 
Sox2 was chosen, because its expression has been more consistently linked to non granule 
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cell progenitors (Sottile et al., 2006) and NSCs (Suh et al., 2007). Sox2 expression was found 
in five out of 13 medulloblastoma samples (Fig.5a) but no significant expression was seen in 
three medulloblastoma cell lines (DAOY, D341 and D458). Similar expression of Sox2 was 
found in the majority of glioblastomas (unrelated malignant CNS tumours of astrocytic lineage) 
analysed (Fig.4a). To scale up the analysis and to correlate Sox2 expression to specific 
histological and biological parameters we generated a TMA from 71 human medulloblastoma 
samples. Eighteen cases showed widespread nuclear positivity for Sox2, while 53 cases were 
negative. Interestingly, statistically significant higher number of Sox2 positive 
medulloblastomas were found in the adult population, while Sox2 negative tumours were more 
frequent in children (63% and 14% Sox2 positive cases respectively, p=0.0001). We found that 
the majority of Sox2 positive cases were also expressing nestin (67%, p=0.0331). 
A recent study showed similar robust positivity for Sox2 in glial tumours, which was associated 
with the expression of glial specific markers (Phi et al., 2008). However, we found no co-
expression of Sox2 and GFAP in our series of medulloblastoma (Fig.4c), suggesting that Sox2 
expression in medulloblastoma is restricted to a subset of tumours, in agreement with previous 
data (de Bont et al., 2008; Shu et al., 2008) and not a general phenomenon related to glial 
differentiation as in glioblastoma.  
These findings show that in both our mouse model and in human medulloblastoma samples, 
expression of NE stem cell markers identifies a subtype of medulloblastoma and raise the 
possibility that this subset of tumours originate from cNSCs. The possibility that they might 
originate from Bergmann glia, which is also Sox2 positive, was considered, however it seems 
unlikely as Bergmann glia does not express CD133 (GENSAT) and would therefore not have 
been enriched for with our method. Moreover, expression of GFAP was found not to co-
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localise with expression of Sox2 in the human samples. Interestingly, in humans these tumours 
were more often found among the adult population, indeed expression of Sox2 and Math1 
(data not shown), which is expressed in medulloblastoma originating from GCPs also in human 
(Lee et al., 2003; Zhao et al., 2008) was mutually exclusive in our tumour series. 
 
Expression analysis has shown activation of the Shh pathway in the majority of human 
medulloblastoma (Pomeroy et al., 2002), despite the fact that mutations in members of the 
pathway are only found in a subset of tumours. To assess Shh pathway activation we 
performed RNA in situ hybridisation for Gli1 (Fig.3b) and immunohistochemistry for Bcl2 
(Fig.3b) and found 39 (55%) and 25 (35%) positive cases respectively. Medulloblastoma 
expressing Gli1 were frequently co-expressing Bcl2 (49% versus 4.5% Bcl2 positive cases in 
the Gli1 negative group, p=0.0013), in keeping with the interpretation of their expression to 
indicate Shh pathway activation (Bar et al., 2007; Bigelow et al., 2004; Lee et al., 1997). The 
positive correlation between expression of Gli1 and Math1, which characterises 
medulloblastoma originating from EGL progenitor cells (p=0.0057) is in keeping with the notion 
that deregulation of the Shh pathway plays a crucial role in the pathogenesis of 
medulloblastoma arising from the EGL (Kimura et al., 2005; Romer et al., 2004; Taylor et al., 
2002). Surprisingly, a significant association was found also between expression of Sox2 and 
expression of Gli1 (94%, p=0.003) as well as Bcl2 (83%, p=0.0001). On the contrary, Gli1was 
found to be expressed at even lower level than in the adult cerebellum in our allograft model. 
These data together with the lack of Math1 expression in both murine cNSC medulloblastoma 
and in human sox2-positive medulloblastoma suggest aberrant activation of the Shh pathway 
independently of granule cell commitment in human medulloblastoma. In keeping with this 
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interpretation, a crucial role of Shh in controlling the behaviour of cells with stem cell properties 
in the mouse embryonic neocortex (Palma & Ruiz i Altaba, 2004) and the proliferation of NSC 
in the adult murine brain (Palma et al., 2005) has been demonstrated. 
Nuclear β-catenin immunoreactivity, indicative of Wnt/Wg activation, as well as mutations 
affecting components of this pathway have been reported in 25% and 15% of cases of human 
medulloblastoma respectively (Ellison et al., 2005; Huang et al., 2000). Moreover, an 
association between mutations in this pathway and a putative origin of this subgroup of 
tumours from NSCs has been hypothesised (Gilbertson & Ellison, 2008). We found strong 
nuclear positivity for β-catenin (Fig.3b) in a majority of tumour cells only in 3 cases and none of 
them expressed Sox2. Moreover, no nuclear expression of β-catenin was seen in murine 
cNSC medulloblastoma. 
 
Furthermore we set out to analyse whether the expression of stem cell markers Sox2 and 
Nestin either alone or in combination would influence disease progression and survival. 
Paediatric patients with Sox2 negative medulloblastoma had a longer disease-free interval 
compared to those with Sox 2 expression (Fig.5d, p=0.0015). A similar trend was observed 
also among the adult population, where the percentage of tumours expressing Sox2 was 
higher, however the data did not reach statistical significance due to the smaller number of 
cases (Fig.5d). Nestin expression alone was not significantly associated with clinical outcome. 
However, co-expression of Sox2 and nestin was associated with a significantly shorter survival 
rate (Fig.5d, p=0.039). It is intriguing that double labelling for Sox2 and nestin in postnatal 
human cerebellum showed scattered cells expressing both markers within the cerebellar white 
matter (Fig.5e) as observed in the mouse cerebellum (Fig.4f). These findings suggest that cells 
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with stem cell properties might exist in the postnatal human cerebellum and they might be 
involved in medulloblastoma pathogenesis as we have shown in our mouse model. 
 
Medulloblastoma show a heterogeneous biological behaviour which is reflected in the wide 
spectrum of clinical outcome and response to therapy. Despite considerable progress in the 
clinical management of these patients which resulted in an improvement of overall survival, the 
long-term side effects of the aggressive therapeutic regimen used are often severe. Here we 
have shown that medulloblastoma can originate from endogenous postnatal cerebellar NSCs 
and that they retain a molecular signature related to their origin in a mouse model. Moreover, 
we have demonstrated that this molecular signature identifies a subgroup of human 
medulloblastoma associated with a more aggressive clinical behaviour. Understanding the 
ontogeny and the closely linked molecular mechanisms involved in medulloblastoma 
pathogenesis is key to achieve a better therapeutic stratification of patients and to identify 
novel drugable targets to improve the outcome of these highly aggressive neoplasms. 
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Figure legends 
Fig.1:
a) Math1-driven expression of GFP in GCPs of the EGL at P7.  
b) GFP-positive GCPs in the CD133-negative fraction, (left; overlay bright field and 
fluorescence) and GFP-negative NS derived from cNSCs in the CD133-positive fraction (right; 
overlay bright field and fluorescence).  
c) Flow cytometry shows lack of GFP positive cells in single cells obtained after dissociation of 
tertiary NS. d) No expression of GFP in these cells (visual confocal).  
e) Quaternary NS arising from d) show no GFP positive cells. 
f) NS shows expression of stem cell markers CD133 and Nestin (upper row), as well as Sox2 
and Bmi1 (lower row) in a proportion of cells.  
g) Trilineage multipotency of cNSC (GFAP astrocytes, β III tubulin neurons and O4 
oligodendrocytes) upon induction of differentiation.  
Scale bar is 2mm, 500μm, 80μm, 240μm respectively in a, 240μm in b, 500μm in c. 
 
Fig.2
a) High infection rate of cNSCs upon infection with Adeno-GFP, as assessed by GFP positivity 
in the NS originating thereof (upper row, left and middle) and high efficiency of recombination 
upon Adeno-Cre infection, as assessed by X-gal staining (upper row, right). 
b) PCR analysis of Cre-mediated recombination of floxed Rb allele (left) and floxed p53 allele 
(right) shows complete recombination of the former and partial, albeit highly significant, 
recombination of the latter. NS: Neurospheres, -C: Unrecombined, +C: Recombined, wt: Wild 
type control, Fl: Homozygous floxed control. 283-bp (unrecombined floxed Rb allele), 260-bp 
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(recombined Rb 19 allele), and 235-bp (wild type Rb allele) and 612-bp (recombined p53 
allele). 
c) Higher viability of cNSCs lacking Rb/p53 (blue) as compared to control cNSC (green) [n=3]. 
AlamarBlue assay. Error bars represent SD. p=0.012. 
d) Increased size and number of NS lacking Rb/p53 (upper row) as compared to control (lower 
row). 
e) Higher self-renewal of cNSC lacking Rb/p53 at various cell densities (blue) as compared to 
control (green) [n=3]. Serial dilutions (from 500 cells to 4 cells per well) were seeded in 24-well 
plates and the number of resulting viable NS were counted after 5 days in culture. The results 
of NS counting were plotted into self-renewal curves. Error bars represent SD. p=0.027.  
f) Resistance to apoptosis in NS lacking Rb and p53 as assessed by Annexin V staining and 
flow cytometry [n=4], graph and dot plots. Error bars represent SD. p=0.006. 
g) Tendency toward a reduced differentiation potential of cNSCs lacking Rb and p53 [n=3], as 
assessed by immunostaining for GFAP, βIII Tubulin and O4. Error bars represent SD. n.s. 
Scale bar is 500μm in d and e. 
 
Fig.3:
a) Subcutaneous tumour arising 67 days after injection of cNSCs lacking Rb/p53 in a R26R-
LacZ background into NOD SCID mice (right) originates from cNSCs, as assessed by X-gal 
staining. Histological features (H&E) and marker expression (Synaptophysin, NSE and Map2) 
confirmed the diagnosis of medulloblastoma. 
b) qRT-PCR analysis shows no significant difference in Math1 expression levels between 
transformed pre-injection cNSC and cNSC medulloblastoma and tissue known not to express 
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Math1 such as adult cerebellum and adult skeletal muscle. Expression of Math1 is high in EGL 
medulloblastoma and in ptc+/- medulloblastoma.  
c) No expression of GABARα6 and only very weak expression of Gli1 in all three cNSC 
medulloblastoma and high expression of the genes in the adult cerebellum and in 2/3 EGL 
medulloblastoma 
 
Fig.4:
a) Histological and immunohistochemical characterisation of cNSC medulloblastoma (upper 
row) and EGL medulloblastoma (lower row) shows strong and homogeneous expression of 
Nestin, Sox2 and Sox9 in NSC medulloblastoma. Only few scattered cells are positive in EGL 
medulloblastoma.  
b) Upregulation of Sox2 expression is not seen in EGL medulloblastoma (western blot 
analysis) as compared to the weak expression seen in the adult human cerebellum. 1-6: EGL 
medulloblastoma samples; A: Adult cerebellum; Co: medulloblastoma. This blot was hybridized 
and analyzed together with the blots shown in Fig.5a.  
c) Only scattered Sox2 positive cells are detected in Ptc+/- medulloblastoma.  
d) Strong expression of Sox2 and Sox9 in NE cells (upper row, arrows) and only very few cells 
weakly expressing Sox2 in the EGL (lower row, arrows and inset) at E18.5.  
e) Expression of Sox2 in Bergmann glia and in scattered cells in the IGL and white matter in 
P7 cerebellum. No expression of Sox2 is seen in highly proliferating GCPs (BrdU staining). 
Both Bergmann glia and cNSCs co-express Sox2 and Nestin (arrows and schematic 
representation of their anatomical location). 
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f) Sox2 positive cells are seen in the IGL and at the boundary between IGL and white matter in 
the adult cerebellum (arrows). 
Scale bar is 4mm, 1mm, 125μm respectively in a, 125μm in b, 250μm and 80μm respectively 
in c, 250μm in d, 125μm in e and g. 
 
Fig.5:
a) Increased expression of Sox2 in a subset of human medulloblastoma but no increased 
expression in three medulloblastoma cell lines. High expression of Sox2 in the majority of 
human glioblastoma analysed. 1-14: human medulloblastoma samples; three medulloblastoma 
cell lines: DAOY, D341, D458; 1-8: human glioblastoma samples; Co: positive control.  
b) Examples of expression of Sox2, nestin, Bcl2, Gli1 (antisense and sense control) and 
βcatenin in human medulloblastoma TMA.  
c) No co-localisation of the expression of Sox2 and GFAP in human medulloblastoma. 
d) Sox2 expression and disease progression in children (upper row) and adults (middle row). 
Co-expression of Sox2 and nestin and tumour specific survival (lower row).  
e) Co-expression of stem cell markers Nestin and Sox2 in scattered cells in the IGL and white 
matter of the postnatal human cerebellum (arrows).  
Scale bar is 80μm. 





